Get the Stockscreener App
0.812
1.12%
-0.0155
Adaptimmune Therapeutics Plc Adr stock is traded at $0.812, with a volume of 331.28K.
It is down -1.12% in the last 24 hours and down -13.96% over the past month.
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
See More
Previous Close:
$0.8275
Open:
$0.8178
24h Volume:
331.28K
Relative Volume:
0.26
Market Cap:
$209.23M
Revenue:
$60.28M
Net Income/Loss:
$-113.87M
P/E Ratio:
-1.5212
EPS:
-0.5338
Net Cash Flow:
$-145.76M
1W Performance:
+16.14%
1M Performance:
-13.96%
6M Performance:
-31.24%
1Y Performance:
+46.11%
1-Day Range:
$0.792
$0.8238
1-Week Range:
$0.6702
$0.8552
52-Week Range:
$0.42
$2.05
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
Name
Adaptimmune Therapeutics Plc Adr
Sector
Industry
Phone
44 1235 430000
Address
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-09-22 | Upgrade | Mizuho | Neutral → Buy |
| May-28-21 | Initiated | Barclays | Underweight |
| Apr-22-20 | Initiated | Mizuho | Neutral |
| Aug-02-19 | Downgrade | Guggenheim | Buy → Neutral |
| May-31-19 | Initiated | ROTH Capital | Buy |
| May-30-19 | Resumed | Citigroup | Buy |
| May-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-17-17 | Initiated | Wells Fargo | Market Perform |
| Oct-24-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Sep-30-16 | Initiated | Raymond James | Outperform |
| Feb-25-16 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | BofA/Merrill | Neutral |
| Jun-01-15 | Initiated | Guggenheim | Buy |
| Jun-01-15 | Initiated | Leerink Partners | Outperform |
View All
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Latest News
Adaptimmune faces Nasdaq delisting over share price - Investing.com India
NVIDIA Corp (NVDA): Be Patient, You Will Learn - Stocks Register
Investing in HUYA Inc ADR (HUYA): What You Must Know - Knox Daily
Checking in on Blackstone Inc (BX) after recent insiders movement - Knox Daily
Ready to Jump After Recent Trade: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Ratio Examination: Adaptimmune Therapeutics Plc ADR (ADAP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Was anything negative for Adaptimmune Therapeutics Plc ADR (ADAP) stock last session? - US Post News
Chief Commercial Officer Piccina Cintia sale 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP] - Knox Daily
The Significance of Moving Averages in Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance - The InvestChronicle
Technical analysis of Adaptimmune Therapeutics Plc ADR (ADAP) stock chart patterns - US Post News
Adaptimmune Therapeutics Plc ADR (ADAP)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
A significant driver of top-line growth: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Analysts review Adaptimmune Therapeutics Plc ADR’s rating - Knox Daily
How should investors view Adaptimmune Therapeutics Plc ADR (ADAP)? - US Post News
Recent Insider Activity Could Benefit Zentalis Pharmaceuticals Inc (ZNTL) - Knox Daily
Wall Street SWOT: Adaptimmune stock faces challenges despite FDA win - Investing.com
Stocks of Adaptimmune Therapeutics Plc ADR (ADAP) are poised to climb above their peers - SETE News
Insider Sale Alert: Gap, Inc. [GAP] – Is it Time to sell? - Knox Daily
Adaptimmune Therapeutics Plc ADR [ADAP] Piccina Cintia sells 24,531 Shares for $22814.0 - Knox Daily
Adaptimmune finalizes settlement with Genentech - Investing.com India
ADAP’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Ratios Uncovered: Breaking Down Adaptimmune Therapeutics Plc ADR (ADAP)’s Trailing Twelve Months Metrics - The Dwinnex
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Yahoo Finance UK
Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance: Is It Undervalued or Overvalued? - The InvestChronicle
Recent Insider Activity Could Benefit Adaptimmune Therapeutics Plc ADR (ADAP) - Knox Daily
Zumiez Inc’s latest rating changes from various analysts - Knox Daily
AdaptHealth Stock Earns RS Rating Upgrade - MSN
A new trading data show Adaptimmune Therapeutics Plc ADR (ADAP) is showing positive returns. - SETE News
Predicting Adaptimmune Therapeutics Plc ADR’s (ADAP) earnings for the current quarter - US Post News
Director SIMON WILLIAM E JR acquire 45,000 shares of Douglas Emmett Inc [DEI] - Knox Daily
Buying Buzz: Noble Corp Plc [NE] 10% Owner APMH Invest A/S purchases 324,984 shares of the company - Knox Daily
There is no doubt that Adaptimmune Therapeutics Plc ADR (ADAP) ticks all the boxes. - SETE News
Analyzing Ratios: Adaptimmune Therapeutics Plc ADR (ADAP)’s Financial Story Unveiled - The Dwinnex
Adaptimmune Therapeutics Plc ADR (ADAP) stock analysis: A simple moving average approach - US Post News
A company insider recently sold 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP]. Should You Sale? - Knox Daily
EWCZ Shares Experience Decline in Value - Knox Daily
Natera Inc [NTRA] Shares Jump Approximately 97.71% Over the Year - Knox Daily
Adaptimmune Therapeutics Plc ADR’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Premier Inc [PINC] Shares Fall -1.35 % on Thursday - Knox Daily
An analyst sees good growth prospects for Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Closing Figures: Adaptimmune Therapeutics Plc ADR (ADAP)’s Negative Finish at 1.16, Down -4.13 - The Dwinnex
Analyzing Adaptimmune Therapeutics Plc ADR (ADAP) After Recent Trading Activity - Knox Daily
Adaptimmune Therapeutics Plc ADR (ADAP) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Market Recap Check: Adaptimmune Therapeutics Plc ADR (ADAP)’s Negative Finish at 1.24, Up/Down -6.77 - The Dwinnex
Adaptimmune Therapeutics Plc ADR: Rising -35.12% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
A closer look at Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price trends - US Post News
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
A better buy-in window may exist right now for Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Financial Analysis: Adaptimmune Therapeutics Plc ADR (ADAP)’s Ratios Unveil Key Insights - The Dwinnex
The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - US Post News
It is Poised to be a Bull Market for Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rawcliffe Adrian | Chief Executive Officer |
Jan 17 '24 |
Sale |
0.67 |
30,080 |
20,244 |
44,848 |
| Rawcliffe Adrian | Chief Executive Officer |
Jan 16 '24 |
Sale |
0.79 |
9,304 |
7,350 |
14,104 |
| Norry Elliot | Chief Medical Officer |
Jan 17 '24 |
Sale |
0.67 |
18,276 |
12,300 |
7,785 |
| Norry Elliot | Chief Medical Officer |
Jan 16 '24 |
Sale |
0.79 |
2,287 |
1,807 |
3,363 |
| Lunger John | Chief Patient Supply Officer |
Jan 17 '24 |
Sale |
0.67 |
18,114 |
12,191 |
7,785 |
| Lunger John | Chief Patient Supply Officer |
Jan 16 '24 |
Sale |
0.79 |
4,681 |
3,698 |
7,023 |
| Bertrand William C JR | Chief Operating Officer |
Jan 17 '24 |
Sale |
0.67 |
18,908 |
12,725 |
7,785 |
| Bertrand William C JR | Chief Operating Officer |
Jan 16 '24 |
Sale |
0.79 |
4,681 |
3,698 |
7,023 |
| Norry Elliot | Chief Medical Officer |
Jan 12 '24 |
Sale |
0.85 |
7,799 |
6,661 |
11,841 |
| Norry Elliot | Chief Medical Officer |
Jan 11 '24 |
Sale |
0.84 |
4,009 |
3,354 |
6,104 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):